Description: A Phase 1 / 2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Mechanism of Action: anti-ILT2/ILT4 monoclonal antibody (activates myeloid cells).
Target Patient Population: Most Solid Tumors
Study Design: Drug is given IV every 3 weeks